Table 1 Clinical information of HCC patients in each cohort
From: A new prediction model of hepatocellular carcinoma based on N7-methylguanosine modification
Covariates | Type | Total | Test | Train | P value |
|---|---|---|---|---|---|
Age |  <  = 65 | 227 (62.19%) | 108 (59.34%) | 119 (65.03%) | 0.3114 |
Age |  > 65 | 138 (37.81%) | 74 (40.66%) | 64 (34.97%) |  |
Gender | FEMALE | 119 (32.6%) | 58 (31.87%) | 61 (33.33%) | 0.8517 |
Gender | MALE | 246 (67.4%) | 124 (68.13%) | 122 (66.67%) | Â |
Grade | G1 | 55 (15.07%) | 27 (14.84%) | 28 (15.3%) | 0.5333 |
Grade | G2 | 175 (47.95%) | 81 (44.51%) | 94 (51.37%) | Â |
Grade | G3 | 118 (32.33%) | 65 (35.71%) | 53 (28.96%) | Â |
Grade | G4 | 12 (3.29%) | 6 (3.3%) | 6 (3.28%) | Â |
Grade | unknown | 5 (1.37%) | 3 (1.65%) | 2 (1.09%) | Â |
Stage | Stage I | 170 (46.58%) | 89 (48.9%) | 81 (44.26%) | 0.3657 |
Stage | Stage II | 84 (23.01%) | 36 (19.78%) | 48 (26.23%) | Â |
Stage | Stage III | 83 (22.74%) | 43 (23.63%) | 40 (21.86%) | Â |
Stage | Stage IV | 4 (1.1%) | 1 (0.55%) | 3 (1.64%) | Â |
Stage | unknown | 24 (6.58%) | 13 (7.14%) | 11 (6.01%) | Â |
T | T1 | 180 (49.32%) | 92 (50.55%) | 88 (48.09%) | 0.619 |
T | T2 | 91 (24.93%) | 42 (23.08%) | 49 (26.78%) | Â |
T | T3 | 78 (21.37%) | 42 (23.08%) | 36 (19.67%) | Â |
T | T4 | 13 (3.56%) | 5 (2.75%) | 8 (4.37%) | Â |
T | unknown | 3 (0.82%) | 1 (0.55%) | 2 (1.09%) | Â |
M | M0 | 263 (72.05%) | 126 (69.23%) | 137 (74.86%) | 0.3655 |
M | M1 | 3 (0.82%) | 1 (0.55%) | 2 (1.09%) | Â |
M | unknown | 99 (27.12%) | 55 (30.22%) | 44 (24.04%) | Â |
N | N0 | 248 (67.95%) | 122 (67.03%) | 126 (68.85%) | 0.5265 |
N | N1 | 4 (1.1%) | 1 (0.55%) | 3 (1.64%) | Â |
N | unknown | 113 (30.96%) | 59 (32.42%) | 54 (29.51%) | Â |